Raptor Pharmaceuticals Acquires Orphan Clinic...(to further support and expand its covera...)

Bennu executes the clinical development of internal products and in- licensed candidates that are: 1) new chemical entities in mid-to-late stage clinical development; 2) currently approved drugs with potential efficacy in additional indications; and 3) treatments that Bennu could repurpose or reformulate as potentially more effective or convenient treatments for their currently approved indications. Bennu's initial clinical programs include the treatment of aldehyde dehydrogenase ("ALDH2") deficiency and nephropathic cystinosis.
For additional information, please visit http://www.raptorpharma.com.

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the following statements: the Company's ability to develop a safer and more effective treatment for nephropathic cystinosis; the Company's ability to conduct clinical trials and to address the unmet needs in metabolic and neurodegenerative diseases; the ability of EC Cysteamine to add value and balance to our clinical portfolio; the Company's ability to improve compliance and utilization of EC cysteamine in cystinosis patients and expand the treatment population; the Company's ability to address Huntington's disease and Batten disease; and the Company's ability to introduce EC cysteamine quickly to cystinosis patients as well as to initiate trials in new indications. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause our actual results to be materially different from these forward- looking statements
'/>"/>